Clinical trials: Benign Prostate Hypertrophy(BPH)
Benign Prostate Hypertrophy(BPH), Renal Calculi
Stone and Laser Therapies Post-Market Study (SALT)
The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary tract procedure (e.g.…
- Conditions
- Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary
- Trial name
- SALT (NCT06982235)
- Testing
- Ureteroscope system, Laser system
- Where
- 5 sites in United States
- Volunteers
- 238 people
- Sponsor
- Boston Scientific Corporation
Acute Urinary Retention, Benign Prostate Hypertrophy(BPH)
Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention
This randomized, double-blind, placebo-controlled Phase 2 study is evaluating Teverelix DP in men following a first episode of acute urinary retention (AUR) associated with benign prostatic hyperplasia (BPH), a population at risk…
- Trial name
- NCT07733934
- Testing
- Teverelix DP
- Volunteers
- 126 people
- Sponsor
- Antev Ltd.
Benign Prostate Hypertrophy(BPH)
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846
- Trial name
- NCT07404735
- Testing
- CKD-846, D091
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Benign Prostate Hypertrophy(BPH)
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
A Clinical trial to compare and evaluate evaluate the pharmacokinetics and safety of CKD-846
- Trial name
- NCT06110923
- Testing
- CKD-846, D091
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Prostate Disease, BPH
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
Multi-center, prospective randomized dosing and safety research study. A maximum of 150 men will be enrolled in the study. Qualifying patients will receive one of three possible doses of the study drug.
- Conditions
- Prostate Disease, BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00037141
- Testing
- dehydrated alcohol
- Volunteers
- 150 people
- Sponsor
- American Medical Systems